Chargement en cours...
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis
BACKGROUND. In the U.S., the addition of bevacizumab to first‐line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality‐adjusted life years (QALYs) at an incremental cost‐effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value fo...
Enregistré dans:
| Publié dans: | Oncologist |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AlphaMed Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5469597/ https://ncbi.nlm.nih.gov/pubmed/28592621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0455 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|